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Abstract 
To date, the role of nanoparticle surface hydrophobicity has not been investigated 
quantitatively in relation to pulmonary biocompatibility. A panel of nanoparticles spanning 
three different biomaterial types, pegylated lipid nanocapsules, polyvinyl acetate (PVAc) and 
polystyrene nanoparticles, were characterized for size, surface charge, and stability in 
biofluids. Surface hydrophobicity of five nanoparticles (50-150 nm) was quantified using 
hydrophobic interaction chromatography (HIC) and classified using a purpose-developed 
hydrophobicity scale: the HIC index, range 0.00 (hydrophilic) to 1.00 (hydrophobic). This 
enabled the relationship between the nanomaterial HIC index value and acute lung 
inflammation after pulmonary administration to mice to be investigated. The nanomaterials 
with low HIC index values (between 0.50-0.64) elicited little or no inflammation at low (22 
cm
2
) or high (220 cm 
2
) nanoparticle surface area doses per animal, whereas equivalent 
surface area doses of the two nanoparticles with high HIC index values (0.88-0.96) induced 
neutrophil infiltration, elevation of pro-inflammatory cytokines and adverse histopathology 
findings. In summary, a HIC index is reported that provides a versatile, discriminatory, and 
widely available measure of nanoparticle surface hydrophobicity. The avoidance of high (HIC 
index > ~0.8) surface hydrophobicity appears to be important for the design of safe 
nanomedicines for inhalation therapy. 
 
Keywords: Nanomedicine; nanoparticles; pulmonary drug delivery; 
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Introduction 
 
Inhalation of drug-containing nanoscale carriers has been heralded as an important 
strategy for the local or systemic delivery of therapeutic agents to or via the lungs  [1-5]. 
Inhaled nanocarriers have the potential to control drug release, prolong lung retention, target 
drug to specific sites in the lungs and reduce off-target side effects  [6, 7]. For successful 
development as inhaled medicines, however, careful biomaterial design is required to avoid 
lung toxicity. Paradigms are emerging to link specific physicochemical properties of 
nanoparticles with acute lung toxicity (e.g. tissue damage, cellular influx or cytokine release) 
or long term adverse effects such as chronic inflammation, fibrosis, or lung cancer  [8-12]. For 
example, there is a large body of evidence relating respiratory toxicity to nanoparticle 
properties such as chemically reactive surfaces, including those which generate reactive 
oxygen species [13], highly cationic or anionic surfaces  [14-16], high particle aspect ratio 
[17], excessive surface area exposure of inert nanomaterials  [18, 19], and biopersistence in 
the lungs [20]. Nanomedicine design strategies which avoid or mitigate these risk factors have 
been shown to result in enhanced biocompatibility profiles in vivo  [15, 21-23]. 
Surface hydrophobicity is often cited as an additional risk factor for nanoparticle toxicity  
[20,  24, 25], but is seldom, if ever, characterized during nanoparticle profiling, which typically 
concentrates on particle size, shape, zeta potential, crystallinity, colloidal stability, surface 
reactivity, and solubility/degradability [12]. The rare studies that have investigated the 
relationship between nanoparticle surface hydrophobicity and in vivo respiratory toxicity [15], 
appear to indicate a relationship, but have lacked a quantitative metric for hydrophobicity. 
Several analytical methods are available to quantify nanoparticle hydrophobicity, including 
small molecule adsorption assays (i.e. dyes, hydrophobic compounds, water)  [26-28] and 
hydrophobic interaction chromatography (HIC) [29], each of which has advantages and 
limitations. 
Methods that measure small molecule adsorption to the particle surface provide a highly 
information-rich characterisation of the molecular interaction forces at the particle surface. For 
example, Xia et al  [24, 25] studied the adsorption profiles of 28 different small molecule probes to 
the surface of multi-walled carbon nanotubes and their carboxylated derivatives using solid phase 
microextraction gas chromatography/mass spectroscopy. Numerical data representing five 
descriptors (hydrophobicity, hydrogen bonding, polarity, polarizability, and lone-pair electrons) 
were combined into a single value, the biological surface adsorption index (BSAI) score, which was 
proposed for use in modelling quantitative structure-activity relationships. Although this approach 
is excellent for in-depth analysis of nanoparticle surfaces, its implementation as a routine screening 
method is limited by the complexity and prolonged duration of analysis, as well as the requirement 
of specialized analytical equipment. 
The aims of this study were to develop HIC as a quantitative method for measuring 
nanoparticle surface hydrophobicity and investigate the influence of nanoparticle surface 
hydrophobicity on pulmonary biocompatibility. An HIC index value was developed to provide 
a quantitative descriptor of nanoparticle surface hydrophobicity and used to score five 
nanoparticle systems based on three different biomaterial types. Polystyrene (PS) nanoparticles 
were used as a high hydrophobicity reference nanomaterial reported to elicit an acute 
inflammatory response in the lung at elevated exposure doses  [18, 19,  22]. Nanoparticles 
fabricated from two different grades of polyvinyl acetate (PVAc) were included as 
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representative of polymeric systems previously investigated to serve as inert reference particles 
in inhalation toxicology studies  [30] and are also found in some aerosolized consumer 
products, including hairsprays [31]. Two lipid nanocapsule (LNC) formulations (nanocarriers 
characterized by a liquid triglyceride core and a solidified phospholipid shell containing 
pegylated 12-hydroxystearate) were included in the study to exemplify promising 
nanomedicine formulations for pulmonary delivery of poorly soluble compounds  [32-36]. 
The nanoparticle systems included in the study were designed such that they would 
display a range of surface hydrophobicities. All the nanoparticles were chemically inert, 
amorphous, spherical with diameters of either 50 or 150 nm and had a negligible surface 
charge. The hypothesis of the study was that increasing nanoparticle surface hydrophobicity, as 
measured by HIC, would correlate with acute respiratory toxicity when administered to the 
lungs of mice. 
 
Materials and Methods 
Two molecular weight grades of PVAc, high (48 kDa) and low (12.8 kDa), were 
purchased from Sigma-Aldrich (Dorset, UK). Poly vinyl alcohol (PVA; 8-12 kDa) was 
purchased from Sigma-Aldrich (Dorset, UK). Labrafac
®
 Lipophile WL1349 was obtained from 
Gattefosse (Saint-Priest, France), Solutol
®
 HS15 was acquired from BASF (Ludwigshafen, 
Germany) and Lipoid
®
 S75-3, from Lipoid GmbH (Ludwigshafen, Germany). Non-modified 
polystyrene nanoparticles with a diameter of 50 nm (2.62% m/v) were used as a reference 
material and were purchased from Polysciences (Eppelheim, Germany). All other materials were 
of analytical grade. 
 
2.1 Nanoparticle fabrication 
2.1.1 PVAc nanoparticles 
 
To produce differential degrees of hydroxylation, the PVAc polymers were modified by 
direct saponification according to the method described by Chana et al  [37] producing a PVAc 
polymer with 17 mol% hydroxyl groups and 83 mol% residual acetate groups (PVAc80%) 
from the high molecular weight precursor and a modified PVAc polymer with 34 mol% 
hydroxyl groups and 66 mol% residual acetate groups (PVAc60%) from the low molecular 
weight polymer. Polymer purity and degree of hydrolysis were verified by NMR analysis prior 
to use [37]. PVAc60% nanoparticles were prepared by injecting a solution of 5% w/v 
PVAc60% polymer dissolved in 2:1 methanol:water into a 0.33% w/v aqueous PVA solution, 
whilst stirring at 3500 rpm using a Silverson L4 homogenizer (Silverson Machines Ltd., 
Waterside, UK). PVAc80% nanoparticles were prepared by injecting a solution of 1% w/v 
PVAc80% polymer dissolved in 2:1 methanol:water into a 0.33% w/v aqueous PVA solution, 
whilst stirring at 3500 rpm. Following 30 min constant stirring at 4000 rpm and solvent 
evaporation overnight (~100 rpm), the nanosuspensions were dialyzed against water (72 h) to 
remove excess PVA and subsequently concentrated to the desired final concentration using 
ultrafiltration centrifuge tubes (100 kDa MWCO; Millipore, Watford, UK). Residual PVA was 
quantified colorimetrically using a method adapted from Sahoo et al. [38]. 
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2.1.2  Lipid nanocapsules 
LNCs were manufactured using a phase-inversion temperature method [39]. LNC with 
50 nm diameters (LNC50) were prepared by generating a coarse emulsion of 17% w/w 
Labrafac
®
 Lipophile WL1349, 17% w/w Solutol
®
 HS15, and 1.75% w/w Lipoid
®
 S75-3 in a 
3% w/w NaCl solution. This emulsion was then submitted to repeated heating cooling cycles 
(85°, 60°, 85°, 60°, 85°C) before adjusting to 72°C. At this point the mixture was quenched in 
a 2-fold volume of ice water and stirred at room temperature for 5-10 min. LNC with 150 nm 
diameters (LNC150) were prepared and purified using a similar method, but the relative 
concentrations of components were: 25% w/w Labrafac
®
 WL1349, 8.5% w/w Solutol
®
 HS15, 
1.5% w/w Lipoid
®
 S75-3. In the final step of manufacture, the nascent LNC150 nanoparticles 
were diluted with 2.5 volumes of ice cold water. 
Excess stabilizer (Solutol
®
 HS15) was removed from all suspensions by dialysis (72 h) 
against water containing BioBeads
®
 (BioRad, Hertfordshire, UK) and subsequent 
concentration using ultrafiltration centrifuge tubes (Millipore, UK; 100 kDa MWCO). 
Residual Solutol
®
 HS15 was determined colorimetrically[40]. Briefly, following LNC 
purification by ultrafiltration (as described above), a 50 µL aliquot of the ultrafiltrate 
containing Solutol
®
 HS15 was added to equal volumes (600 µL) of chloroform and an 
aqueous solution of ammonium ferrothiocyanate (16.2 g L
-1
 anhydrous ferric chloride; 30.4 g 
L
-1
 ammonium thiocyanate). The biphasic mixture was incubated under gentle stirring for 30 
min at room temperature. The bottom chloroform layer was assayed spectrophotometrically at 
λ= 510 nm and the Solutol
®
 HS15 content determined from a calibration curve. 
 
2.2 Nanoparticle characterization  
2.2.1  Nanoparticle size and zeta potential 
Particle size and zeta potential were determined using a Zetasizer Nano ZS (Malvern, 
Worcestershire, UK). Size was measured at 25°C in purified water and 5% dextrose over four 
weeks to assess storage stability. Stability after aerosolization was assessed by aerosolizing 25 
μL nanoparticles suspended in 5% m/v dextrose with a Microsprayer
®
device (Penn-Century 
Inc.; Wyndmoor, PA, USA) into 1 mL purified water at 25°C. Size stability in biological 
medium was assessed by aerosolizing 25 μL nanoparticles suspended in 5% m/v dextrose into 
HBSS containing 10% v/v FBS at 37°C and measuring particle size at t=0, 0.17, 4 and 24 h. 
Measurements were taken at a scattering angle of 173°. Refractive indices and viscosity values 
were adjusted for each temperature and medium used. While all nanoparticle suspensions were 
size-stable when stored in purified water at 4°C, fresh batches were prepared for each in vivo 
experiment. Zeta potential measurements were performed at 25° C with all suspensions diluted 
in 6.3 mM NaCl. 
 
2.2.2.  Hydrophobic interaction chromatography 
 
Surface hydrophobicity of nanoparticle suspensions (n=3 individual batches) was 
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assessed using HIC [29]. Briefly, nanoparticle suspensions were prepared in PBS (~1 mg mL
-1
) 
and 250 μL eluted through three different HiTrap™ substituted sepharose hydrophobic 
interaction columns: Butyl FF, Phenyl FF (high substitution) and Octyl FF (GE Healthcare Life 
Sciences, Little Chalfont, UK). The eluent was collected in 1 mL fractions and analyzed for 
particle content via turbidity measurement (Lambda 35;Perkin-Elmer, Cambridge, UK; λ=450 
nm). Particles were subsequently eluted from the column using 0.1% Triton X-100. 
Absorbance values were plotted against elution volumes and two area under the curve (AUC) 
values were calculated using Origin™ software. The particle retention in each of the three 
columns was defined according to Equation (1): 
 
(1)  % 𝐶𝑜𝑙𝑢𝑚𝑛 𝑟𝑒𝑡𝑒𝑛𝑡𝑖𝑜𝑛 (%𝑅) = (
𝐴𝑈𝐶 𝑇𝑟𝑖𝑡𝑜𝑛𝑋
𝐴𝑈𝐶 𝑃𝐵𝑆 + 𝐴𝑈𝐶 𝑇𝑟𝑖𝑡𝑜𝑛𝑋
) × 100 
 
The HIC index value was calculated according to Equation (2): 
 
(2) 𝐻𝐼𝐶 𝐼𝑛𝑑𝑒𝑥 =  
(%𝑅𝑏𝑢𝑡𝑦𝑙 × log 𝑃𝑏𝑢𝑡𝑦𝑙) +  (%𝑅𝑝ℎ𝑒𝑛𝑦𝑙 × log 𝑃𝑝ℎ𝑒𝑛𝑦𝑙) + (%𝑅𝑜𝑐𝑡𝑦𝑙 × log 𝑃𝑜𝑐𝑡𝑦𝑙)
(100% × log 𝑃𝑏𝑢𝑡𝑦𝑙) +  (100% × log 𝑃𝑝ℎ𝑒𝑛𝑦𝑙) + (100% × log 𝑃𝑜𝑐𝑡𝑦𝑙)
 
 
whereby, log P values of each column linker were calculated as: 0.47, 0.94 and 2.05 for butyl, 
phenyl and octyl modified columns, respectively. The log P values of the column linkers were  
calculated using Marvin Sketch (version 5.5.0.1,Chem Axon Limited). In the denominator, each 
log P value was multiplied by 100%, which represents the theoretical case of 100% retention on 
each column achieved by a particle with maximum hydrophobicity. 
 
2.3  In vivo safety evaluation 
2.3.1 Nanoparticle dose and pulmonary administration  
Male Balb/c (6–8 weeks old, ~22-25 g; Harlan, UK) were used in acute respiratory 
toxicology studies utilizing a single pulmonary administration of nanoparticles. All 
experiments were in accordance with the U.K. Home Office regulations and approved by the 
King’s College London research ethics committee. Nanoparticles were administered at doses 
of 22 cm
2
 or 220 cm
2
 nanoparticle surface area per animal (equivalent mass doses are listed in 
Table 1). The use of the surface area dose metric is supported by independent studies suggesting 
that nanoparticle surface area is a more robust descriptor of respiratory toxicity for biopersistent 
nanoparticles compared to mass or particle number dose  [19,  41]. For example, it has been shown 
that nanoparticles of different diameters elicit an equivalent inflammatory response when 
administered at equal surface area doses  [18, 19]. Nanoparticle surface area doses were calculated 
from the hydrodynamic diameter of the particles, assuming a density of ca. 1 g cm
-3
 for PVAc 
nanoparticles, 0.96 g cm 
-3
 for LNC (estimated from the density of the main constituent, Labrafac
®
 
WL1349) and 1.05 g cm
-3
 for PS50 (manufacturer’s information). It should be noted that the doses 
used in this study fall within the typical dose ranges used in toxicology assessments of inhaled 
pharmaceutical compounds when determining the ‘no observed adverse effect level’ values in 
nonclinical studies. All suspensions were prepared in sterile dextrose 5% w/v to ensure isotonicity. 
Vehicle controls were prepared by suspending nanoparticles in sterile dextrose 5% w/v and using 
ultrafiltration centrifugation (Millipore, UK; 100 kDa MWCO) to separate the vehicle from the 
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suspension as described above. 
Isoflurane-induced anesthesia (1-3%) was maintained with intraperitoneal injection of 
100 mg kg
-1
 ketamine mixed with 20 mg kg
-1
 xylazine in 0.1 mL saline to allow intratracheal 
dosing with the Microsprayer
®
 aerosolizer. This combination of tranquilizer/dissociative 
yielded a moderate level of anesthesia for15-20 minutes, as assessed by paw pinch withdrawal 
reflex. Mice were suspended at a 45° angle by their upper incisors and nanosuspensions (25 
L) were administered as a coarse aerosol into the lungs using the Microsprayer
®
 device. This 
device was chosen as it has been reported to provide a more homogenous distribution of liquid 
suspensions into murine lungs compared to intratracheal bolus injections [42]. Animals were 
kept warm post-treatment with a heat lamp, then returned to their cages when ambulatory (<15 
min). 
 
2.3.2. Bronchoalveolar lavage, cytology and histopathology  
 
At 24 h after nanoparticle administration, mice were euthanized via terminal anesthesia 
with urethane (2 mg g
-1
 i.p.). The trachea was exposed, cannulated and the lungs were lavaged 
with three aliquots (0.5 mL) of sterile saline. The total number of cells in the cellular fraction of 
the lavage was counted with a Neubauer haemocytometer (Fisher Scientific, Loughborough, 
UK). Differential cell counts were performed using cytospin preparations, i.e. 100 μL BAL 
cellular fraction centrifuged at 300 g for 1 min using a Shandon Cytospin 2 (Shandon Southern 
Instruments, Sewickley, PA, USA) at room temperature. Cells were stained with Diffquick
®
 
(DADE Behring, Marburg, Germany) and a total of 200 cells were evaluated to determine the 
proportion of neutrophils, eosinophils and macrophages using standard morphological criteria. 
Eosinophils were not observed in any of the samples and are not reported. It was assumed that 
at the time point studied, the mononuclear cell population consisted primarily of resident 
alveolar macrophages and therefore lymphocyte numbers were not investigated. The alveolar 
macrophage population was assessed further by evaluating 100 macrophages to subcategorize 
their morphology as normal, finely or coarsely vacuolated. 
Cytokines present in the BAL supernatant were quantified using a murine 7-plex 
proinflammatory cytokine assay (MSD
®
 96-Well Multi-Spot Cytokine Assay; Meso-Scale 
Discovery, Gainsborough, MD, USA) coupled with an MSD Sector Imager, which measures 
cytokine content via electrochemiluminesce. The cytokines analysed were: IFN-γ, IL-1β, IL-6, 
IL-10, IL-12p70, CLCX1, and TNF-α. The only cytokines/chemokines in the BAL samples at 
levels above the limit of quantification wereIL-1β, IL-6, CLCX1, and TNF-α. As a measure of 
tissue integrity, total protein levels in BAL were quantified using a Quick Start™ Bradford 
Protein Assay (Bio-Rad, Hemel Hempstead, UK) according to manufacturer’s instructions. 
 
Lung tissue histopathology was performed in a randomized, blinded study by an 
independent pathologist according to the Organization for Economic Co-operation and 
Development (OECD) guidelines for histopathology assessment in inhalation toxicity studies, 
[43]. Lungs were removed after terminal anesthesia, inflated with 10% formalin, then immersed 
in 10% formalin for at least one week prior to tissue processing. Samples were coded prior to 
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submission to the pathologist, who produced prepared hematoxylin and eosin (HE) stained 
sections and analyzed them according to OECD guidelines. Analysis was performed in five 
animals using five different sections per lung (across different lobes). Frequency data describe 
the number of animals out of five exhibiting an adverse finding, while the severity score (scale 
of 0-5) describes the number of positive adverse findings across the 25 tissue sections in a 
group divided by five. 
 
2.4 In vitro investigations of macrophage responses  
 
2.4.1 Culture conditions 
 
J774 cells (derived from BALB/c mice) were used as a macrophage-like cell line. Cells were 
cultured at 37˚C in a 5% CO2/95% air atmosphere. Culture media consisted of phenol red-free 
Dulbecco’s Modified Eagle Medium (DMEM; Invitrogen, UK), supplemented with 10% v/v foetal 
bovine serum (FBS), 1% m/v penicillin/ streptomycin, and 2 mM L-glutamine. 
 
2.4.2 In vitro evaluation of apoptosis and mitochondrial activity 
 
J774 cells were seeded onto 8-well glass chamber slides (NuncLabTek II, Fisher 
Scientific, Loughborough, UK) at 5 x 10
4
 cells per well and cultured for 24 h to allow for cell 
attachment. Subsequently, the cell culture medium was removed and replaced with 100 μL fresh 
cell culture medium containing 0.5, 1, 5, 10 mg mL
-1
 PVAc60% or PVAc80% nanoparticles. 
Controls were fresh cell culture medium (untreated control) or vehicle control, prepared as 
previously described. After 24 h, 1 µL of NucView™ 488 (caspase 3/7 substrate; Biotium Inc., 
Hayward, CA, USA) and MitoView™ 633 (mitochondrial dye; Biotium Inc., Hayward, CA, 
USA) probe solutions were added. The probes were incubated for 30 min prior to live cell 
imaging using a Leica DMIR E2 confocal microscope (Leica Microsystems, Milton Keynes, 
UK). Transmission images plus fluorescent emissions from NucView™ 488 (ex = 488 nm; 
em = 500-530 nm) and MitoView™633 (ex = 633 nm; em = 648 nm) were collected using 
separate channels at a magnification of 40x. Instrument gain and offset values were adjusted 
using the negative control and remained constant for all subsequent experiments. Images 
obtained from each scan were pseudo-colored green (NucView™ 488) and red 
(MitoView™633). The presented results depict a representative image from n = 3 different 
sections of the same well. The prevalence of apoptotic cells in the total population was 
determined by calculating the percentage of caspase 3/7 positive cells from the total number of 
cells in n=3 different images (~100 cells per image). To conduct a quantitative evaluation of 
mitochondrial activity, cells were seeded at the same density into 96-well plates and treated 
with fresh cell culture medium containing 0.5, 1, 5, 10 mg mL
-1
 PVAc60% or PVAc80% 
nanoparticles. Controls were fresh cell culture medium (untreated control) or vehicle control, 
prepared as previously described. Following 24 h incubation, the 3-(4,5-dimethythiazol-2-yl)-
2,5-diphenyl tetrazolium bromide (MTT) assay was performed using a previously reported 
methodology  [44] with the experiment repeated on two occasions with three replicates at each 
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concentration of test substance. 
 
2.5  Statistical analysis 
SPSS version 20 (IBM, UK) was used for all statistical analyses. HIC index analysis was 
performed using a one way ANOVA comparison with a post-hoc Tukey test. BAL cell counts 
from nanoparticle- and vehicle-challenged mice were compared by using ANOVA on log 
transformed data followed by the Sidak correction. Data pertaining to the different 
macrophage phenotypes and BAL cytokine levels were analysed using Kruskall Wallis 
followed by multiple distribution free post-hoc test. P<0.05 were considered significant and 
denoted as: * p<0.05, ** p<0.01, and *** p<0.001. 
 
3. Results  
3.1 Nanoparticle characterization  
All nanoparticles possessed a narrow size distribution (Table 2) and a slightly negative to 
neutral zeta potential, consistent with the use of non-ionic stabilizers (e.g. polyetheylene glycol 
and polyvinyl alcohol) which were chosen to reduce the impact of high surface charge as a 
confounding factor in the toxicity studies [14]. Following manufacture, all formulations were 
extensively purified resulting in low levels of excess stabilizer in the vehicle (Table 2). 
Although the nanoparticles formed two distinct size groups (~50 and 150 nm) within the panel, 
this was accounted for in subsequent in vivo studies by administration of equivalent surface 
area doses  [19,  41]. 
Surface hydrophobicity was quantified by HIC using three different column chemistries 
to enhance the discriminatory power of the method (Figure 1a). HIC index values were 
calculated on a scale ranging from 0.00 (maximum theoretical hydrophilicity) to 1.00 
(maximum theoretical hydrophobicity). The nanoparticle panel spanned the upper 50% of the 
HIC scale with values ranging from 0.50 ± 0.09 to 0.96 ± 0.04 (Table 2). Statistical analysis 
revealed two groupings in the data: LNC50, LNC150 and PVAc60% nanoparticles had 
significantly lower HIC index values (p<0.05) compared to the high hydrophobicity 
nanoparticles, PVAc80% and PS50 (Figure 1b). A full statistical comparison is provided in 
Supporting Information (Table S1). 
Nanoparticle surface hydrophobicity influenced colloidal stability in different dispersion 
media. All nanoparticle suspensions were stable in water and 5% dextrose at room temperature 
over four weeks. Microsprayer
®
 aerosolization of 25 µL suspension into 1 mL purified water 
did not alter the particle size distribution (Figure 2a-e, red and green traces). However, 
differences in colloidal stability were observed when suspensions were aerosolized into a model 
physiological fluid, i.e. HBSS containing 10% FBS maintained at 37°C. Under those conditions, 
low hydrophobicity systems (LNC50, LNC150 and PVAc60%) remained stable over 24 h 
(Figure 2a-c, blue and black traces), while PVAc80% and PS50 aggregated immediately upon 
exposure to the model physiological fluid (Figure 2d-e, blue traces). At 10 min, the aggregate 
size was two and six-fold the original particle size for the PVAc80% and PS50 systems 
respectively, (Figure 2d-e, black traces). By 24 h the aggregates were too large to measure by 
dynamic light scattering. These observations provide indirect confirmation of the HIC results, as 
the aggregation of neutral nanoparticles in electrolyte solutions is driven primarily by 
hydrophobic interactions [45]. 
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3.2 Impact of high surface hydrophobicity nanoparticles on acute respiratory toxicity 
 
Inflammation was measured as neutrophil influx (Figure 3a), hypercellularity (Figure 
3b) and cytokine levels (Figures 4a-d) in BAL samples 24h post-exposure to the different 
nanoformulations. Elevated BAL protein levels were considered indicative of tissue damage 
and were also measured 24 h nanoparticle post-exposure (Figure 4e). Low hydrophobicity 
nanoparticle systems (HIC index values < 0.7) showed no evidence of inflammation compared 
to PVAc80% and PS50 (HIC > 0.8), which both induced an acute dose-dependent 
inflammatory reaction evidenced through an increase in BAL neutrophils, inflammatory 
cytokines and, to a lesser extent, total cells counts. The high dose of LNC150 and the low 
dose of PVAc60% nanoparticles showed mild evidence of tissue damage; however no further 
trends were observed in the low hydrophobicity nanoparticle group. In contrast, PVAc80% 
and PS 50 nanoparticle exposure induced a significant dose-dependent increase in BAL 
protein content, indicative of acute tissue damage. 
As reported by others  [18, 19,  41], particle size did not appear to influence respiratory 
toxicity; i.e. the smaller PS50 and LNC50 systems produced findings aligned with particles of 
similar hydrophobicity rather than size (Figures 3 and 4). The level of PS50 induced 
inflammation corresponded with that reported in the literature reports for PS beads of similar 
size and surface area dose  [19,  22] (taking into consideration that the total numbers of cells in 
a mouse lung are roughly one magnitude of order lower than that observed in the rat lung [46]). 
At the low surface area dose (22 cm
2
), PVAc80% was the only nanomaterial on the panel to 
elicit an inflammatory response in the form of significantly elevated IL-1β, IL-6 and TNF-α 
levels (Figure 4a-d). At the high surface area dose (220 cm
2
) PVAc80% nanoparticles elicited 
significant release of CXCL1, IL-1β, IL-6 and TNF-α, with PS50 nanoparticles producing 
statistically equivalent responses in all cytokines apart from TNF-α. 
Total protein levels in BAL can be used as a marker of tissue damage [22]. A significant 
dose-dependent increase in BAL protein levels was observed following treatment with 
hydrophobic nanomaterials, PVAc80% and PS50 (Figure 4e). LNC150 treatment at the higher 
dose was also associated with significantly elevated protein levels, indicating potential tissue 
damage or irritation following exposure to these systems. However, a clear mechanism for this 
observation is not obvious from the current data set. For example, if the elevated BAL protein 
levels resulted from a higher exposure level to LNC components, such as the stabilizing 
surfactant, Solutol
®
 HS15, it would be expected that the high dose LNC50 treatment groups 
would show a similar effect, which was not the case. Therefore, this observation requires 
further investigation. 
Lung tissue histopathology, a major component of nonclinical safety studies for inhaled 
pharmaceuticals, was performed in a blinded analysis by an independent pathologist to assess 
toxicity in response to nanoparticle exposure. Histopathology findings (Figure 5) were broadly 
concordant with the results of the BAL analysis (Figures 3 and 4). Animals treated with high 
surface hydrophobicity nanomaterials (Figure 5e-g) showed an elevated incidence of adverse 
effects, with PVAc80% treatment eliciting a more profound response compared to PS50 
according to the pathology report (Figure 5g). Notable findings in response to PVAc60%, 
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PVAc80% and PS50 nanoparticles included evidence of mild perivascular oedema and 
bronchiolar epithelial vacuolation in response to nanoparticle exposure (Figure 5g). Both LNC 
formulations were associated with a lower frequency and severity histopathology findings 
(Figure 5b,c, g), although the high dose LNC150 treatment was associated with reports of acute 
bronchopneumonia in three out of five animals. This observation may be related to the 
significant increase in BAL protein levels observed in this treatment group, although as stated 
previously further studies are required to understand the underlying mechanism. Increased 
numbers of alveolar luminal macrophages were observed after administration of all 
nanoparticle types, although not to levels greater than the vehicle controls (vehicle control 
images provided in Figure S1, Supporting Information). The cause of this elevation in luminal 
macrophage numbers is not currently understood, although qualitative assessment of histology 
data from animals treated with 5% m/v dextrose and 0.9% saline vehicles indicate that the 
dextrose vehicle may be slightly more irritating to the lung (e.g. causing mild bronchial 
epithelial hyperplasia, mild thickening of the alveolar walls and mild increases in alveolar 
macrophage numbers). This hypothesis is currently under investigation in greater detail. It 
should be noted that the dextrose vehicle was necessary in this study to avoid aggregation of 
high hydrophobicity nanomaterials prior to administration. 
 
3.3  Macrophage responses to polymeric nanoparticles. 
Analysis of the BAL macrophage population revealed two distinct morphological 
phenotypes following treatment with polymeric nanoparticles. Firstly, a minority population of 
enlarged macrophages with a finely vacuolated cytoplasm was observed, the frequency of which 
was dose-dependent in the PVAc80% and PS 50 treatment groups (Figure 6a,b). The second 
phenotype consisted of macrophages with a coarsely vacuolated cytoplasm (Figure 6a). This 
phenotype was observed most frequently following treatment with PVAc60% > PVAc80% > PS 
50 (Figure 6c). 
Preliminary in vitro studies performed with PVAc60% and PVAc80% nanoparticles 
indicated that PVAc60% treatment induced the same coarsely vacuolated phenotype in the J774 
cell murine macrophage line (Figure 7c-e) and that this response was dose-dependent. In 
contrast, PVAc80% exposure to J774 cells did not induce the coarsely vacuolated phenotype 
under the conditions tested (Figure 7f-h); however the PVAc80% nanoparticles were observed 
to aggregate substantially in cell culture medium, thus perhaps altering their presentation to 
cells under in vitro conditions. It may be speculated that PVAc60% nanoparticle-related effects 
occur in response to internalized and processed nanomaterials, while PVAc80% effects may be 
driven either by small amounts of internalized particles or by responses to external nanoparticle 
agglomerates. A significant increase in the frequency of apoptotic cells in the total cell 
population was observed at the highest dose tested (10mg/mL) for both PVAc60% and 
PVAc80%, whereby PVAc80% exposure led to a significantly higher prevalence of apoptotic 
cells compared to PVAc60% (p=0.03). The MTT assay and MitoView™688 staining indicated 
that there was no dose-dependent reduction in mitochondrial activity for either nanoparticle 
type, even at the highest concentrations tested (supplementary data, Figure S2). 
 
4. Discussion 
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The nanomaterials investigated in this study were carefully chosen to exhibit a spectrum 
of hydrophobicity values across a range of different material classes. The LNCs were ideal 
representatives of nanomaterials with relatively hydrophilic surfaces because they are highly 
stable colloids under physiological conditions and there is little evidence that the pegylated 
surface is displaced or altered substantially by the presence of biomolecules in physiological 
fluids [47]. The PVAc nanomaterials are equally useful with respect to studying nanoparticle 
hydrophobicity, as the core PVAc polymer can be easily modified via controlled hydrolysis 
generate polymeric NP with a range of hydrophobicity values. Therefore, even if the PVA 
stabilizer is displaced from the particle surface over the duration of the experiment, the 
substantial differences in the hydrophobicity values of the core polymers will ensure that the 
effects of hydrophobicity can still be examined in a valid manner. The observations that the 
more hydrophilic PVAC60% nanoconstructs showed a greater similarity to the pegylated LNC 
in terms of colloidal stability and inflammatory profile provide supporting evidence for validity 
of this approach. 
 
It was hypothesized that increases in nanoparticle surface hydrophobicity would correlate 
with a higher frequency and severity of adverse pulmonary effects, such as acute inflammation and 
tissue damage. This hypothesis was based on reports that show high material hydrophobicity to be 
implicated in the inflammatory foreign body response to implantable medical devices  [48-50] as 
well as studies which demonstrate that hydrophobicity is generally recognized by the immune 
system as a damage-associated molecular pattern  [51,  52]. In order to systematically assess the 
impact of nanoparticle surface hydrophobicity on pulmonary biocompatibility, a versatile and 
accessible quantitative method for surface hydrophobicity analysis was required. The HIC method  
[29] provided the combined advantages of sensitivity, robustness, versatility and accessibility for 
routine evaluation of nanoparticle surface hydrophobicity. To improve the discriminatory power of 
the original HIC assay, nanoparticle systems were eluted through three different HIC columns with 
varying column chemistries and Equation 2 was developed to calculate the HIC index values 
reported here. This approach is simple, sensitive and can be applied to biomaterials of very 
different compositions. 
 
Administration of the five nanoparticle systems at two doses revealed that the two 
nanomaterials with the highest HIC index values (> 0.8) induced significant, dose-dependent 
inflammatory responses and tissue damage, while nanoparticles with lower HIC index values 
(~0.5-0.7) were not inflammatory under the conditions tested. The relationship between 
surface hydrophobicity and respiratory toxicity was not a linear correlation. For example, plots 
(not shown) of the HIC index value vs. number of neutrophils in BAL reveal low coefficient 
of determination values: R
2
=0.1455 at the 22 cm
2
 dose and R
2
=0.2901 at the 220 cm
2
 dose. 
Instead, significant inflammation and tissue damage occurred only in high hydrophobicity 
nanoparticle treatment groups (Figures 3-5). 
 
The relationship between hydrophobicity and toxicity is multifactorial. It is well known 
that proteins and opsonins may absorb more favorably onto a hydrophobic surface, promoting 
recognition by phagocytic cells and differences in intracellular processing  [53, 54]. In the lung, 
this role may be filled by surfactant-associated proteins (SP), in particular SP-A, which has been 
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implicated in recognition and uptake of nanoparticles by alveolar macrophages  [53,  55]. In 
addition, colloidal instability and particle aggregation in the lung lining fluid may be highly 
influential in promoting an inflammatory response or tissue damage. For example, studies have 
shown that biopolymer particles larger than 500 nm exhibit preferential uptake by phagocytic 
cells and elicit a stronger inflammatory response compared to nanoparticles < 500 nm [56]. 
Furthermore, it would appear that the clustering of nanoparticles during aggregation creates a 
new entity with an irregular surface that may present a higher pro-inflammatory potential than 
comparable smooth-surface particles [57]. The in situ formation of nanoaggregate structures in 
lung lining may occur for high surface hydrophobicity particles and it therefore follows that the 
morphology and stability of such constructs might explain, either entirely or in part, the toxicity 
profiles observed for PVAc80% and PS50 particles. Finally, it should be noted that the role of 
mechanical properties, such as particle rigidity / elasticity, has yet to be explored systematically 
in relation to nanoparticle biocompatibility. Banquay et al  [58] have shown that polyacrylamide 
hydrogel nanoparticles with increasing rigidity achieved through increasing crosslinker density 
were internalized by macrophage cells in greater amounts compared to low rigidity 
nanoparticles of the same material. Further, the mechanism of internalization was different, with 
high rigidity nanoparticles being taken up through clathrin-mediated endocytosis, whereas low 
rigidity materials were primarily taken up passively through macropinocytosis. It is possible that 
the low hydrophobicity nanomaterials included in this study (e.g. LNC50, LNC150 and 
PVAc60%) also have a lower rigidity, which might, in addition to the low hydrophobicity, 
contribute to their enhancedbiocompatibility profile. Therefore, this parameter requires further 
study. 
 
The macrophage responses (i.e. elevated numbers of finely and coarsely vacuolated 
macrophages) to polymeric nanoparticles did not appear to be linked to HIC index or pro-
inflammatory potential. Our preliminary investigations with the J774 cell line indicate that the 
finely vacuolated phenotype may be associated with apoptosis, since J774 cells with this 
appearance also showed caspase 3/7 activity (Figure 7). The coarsely vacuolated macrophage 
phenotype has been previously reported following exposure to a wide range of materials, 
including high molecular weight polymers such as polyethylene glycols [59], poorly soluble 
pharmaceuticals [60], insoluble nanomaterials such as carbon nanotubes, gold, zinc oxide, 
titanium dioxide, fullerenes, quantum dots and silica  [61, 62], and biomaterial nanoparticles 
such as non-inflammatory solid lipid nanoparticles  [21,  63]. It may be indicative of autophagy, 
a process which has been increasingly associated with nanoparticle exposure  [61, 64]. 
Autophagy can be triggered by nanoparticle-induced dysfunction or dysregulation of endo-
lysosomal pathways, resulting in the formation of large, double-membrane autophagic 
vacuoles containing cellular debris, such as engulfed material and internal organelles. 
Evidence suggests that autophagy may not necessarily be a direct pathway leading to cell 
death, but rather constitutes an adaptive response to stress [65], although the impact of 
autophagy on long term respiratory health remains to be investigated. 
 
5. Conclusions 
 
Five nanoparticle systems representative of inhaled drug delivery nanoparticles (LNC), 
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consumer products (PVAc), and experimental model particles (PVAc and PS) were used to 
explore whether particle surface hydrophobicity could be quantified and correlated with acute 
respiratory toxicity after pulmonary administration. The results demonstrated that HIC analysis 
is a versatile, simple quantitative technique that is suitable for routine profiling of nanoparticle 
surface hydrophobicity. Further, the HIC index provides a scale to facilitate comparison of 
nanoparticles spanning different material classes, making it useful for quantitative-structure-
activity relationships in biocompatibility studies. 
 
It was demonstrated that high hydrophobicity nanomaterials (HIC index >0.8) induced 
significant acute respiratory toxicity following a single-dose administration, while 
nanoparticles with low/intermediate hydrophobicity (HIC index <0.7) elicited little to no 
inflammatory response or tissue damage. Indeed, the most hydrophilic nanomaterial in this 
study, LNC50, demonstrated a high biocompatibility making this a promising nanoformulation 
to take forward into nonclinical safety studies. In conclusion, the HIC index value offers a 
versatile and accessible method for the quantification of nanoparticle surface hydrophobicity, 
which may be useful in the design of safe nanomedicines for inhalation therapy. 
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Table 1. Nanoparticle dose metrics for in vivo studies. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 2. Physicochemical properties of the five nanoparticles used in this study following 
manufacture. Values listed represent the mean ± standard deviation of n=3 individual 
batches. 
 
 
 
 
 
 
 
 
 
 
 
 
Nanoparticle type 
Surface area dose  
(cm2 per lung) 
Mass dose 
(µg per lung) 
Suspension 
concentration 
(mg mL-1) 
50-nm particles 
(LNC50, PS50) 
22 ~20 ~0.8 
220 ~200 ~8 
150-nm particles 
(LNC150, 
PVAc60%/80%) 
22 ~50 ~2 
220 ~500 ~20 
Nanoparticle type 
Hydrodynamic 
diameter in water 
(nm) 
PDI 
Zeta potential 
in 6.3 mM NaCl 
 (mV) 
Residual stabilizer 
following 
purification  
(mg mL-1) 
LNC50 43 ± 3 0.10 ± 0.03 -7 ± 4 < 0.5 
LNC150 144 ± 3 0.15 ± 0.03 -4 ± 1 < 0.5 
PVAc60% 160 ± 8 0.09 ± 0.03 -3 ± 0 < 0.4 
PVAc80% 172 ± 11 0.15 ± 0.03 -4 ± 1 < 0.4 
PS50 54 ± 3 0.05 ± 0.03 -25 ± 6 Undisclosed 
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Figure captions 
 
Figure 1. HIC index values of the five nanoparticle systems. (a) The retention values (%) 
for each nanoparticle system following elution through butyl-, phenyl- and octyl-modified 
HIC columns are depicted. Values listed represent the mean ± standard deviation of n=3 
individual nanoparticle batches. (b) Calculated HIC index values for three replicate batches 
of each nanoparticle system. (*) p <0.05. 
 
Figure 2. Colloidal stability of the five nanoparticle systems. Representative particle size 
distribution curves of the three low hydrophobicity nanoparticle systems (HIC index <0.7; a-
c) and high hydrophobicity systems (HIC index >0.8; d,e). Particles sizes were measured 
after particle manufacture in water at 25°C (red traces; a-e) and after aerosolization of a 5% 
m/v dextrose suspension into an excess of water at 25°C (green traces; a-e). To model 
nanoparticle stability in physiological fluids, particle sizes were measured after 
aerosolization of a 5% m/v dextrose suspension into an excess of FBS-supplemented HBSS at 
37°C at t= 0 h (blue traces; a-e), t=24h (black traces; a-c) or t=10 min (black traces; d,e). 
All distribution curves are representative of at least n=3 different nanoparticle batches. 
 
Figure 3. Neutrophil influx and hypercellularity in the BAL cellular fraction following 
exposure to nanomaterials with increasing surface hydrophobicity. Neutrophil count (a) 
and total cell count (b) in BAL 24 h post-administration of vehicle control, 22 or 220 
cm
2
surface area dose of nanoparticles to mice. Values represent the mean ± standard 
deviation of n=5-12 animals per group. (*) p <0.05, (**) p < 0.01, (***) p<0.001. 
 
Figure 4. Pro-inflammatory cytokines and total protein content in BAL following exposure 
to nanomaterials with increasing surface hydrophobicity. BAL levels of CXCL1(a), IL-1β 
(b), 
 
IL-6 (c), TNF-α (d) and total protein content (e) in BAL 24 h post-administration of vehicle 
control, 22 or 220 cm
2
surface area dose of nanoparticles to mice. Values represent the 
mean 
± standard deviation of n=5-12 animals per group. (*) p <0.05, (**) p < 0.01, (***) p<0.001. 
 
Figure 5. Histopathology of lung tissue exposed to nanomaterials with increasing surface 
hydrophobicity. Representative images of a naïve lung (a) compared with lung tissue harvested 
from mice 24 h after LNC50 (b), LNC150 (c), PVAc60% (d), PVAc80% (e) or PS50(f) treatment 
at a nanoparticle surface area dose of 220 cm
2
 (20x magnification; scale bars =100 μm). (g) 
Evaluation of the frequency of pulmonary adverse events and severity scores (scale: 0-5) 
based on a blind assessment of lung histopathology by an independent pathologist, n=5 
animals for each nanoparticle type administered. 
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Figure 6. Macrophage responses following exposure to nanomaterials with increasing 
surface hydrophobicity. (a) Representative images (40x magnification) showing 
macrophages from untreated animals (left image), enlarged macrophages with a finely 
vacuolated cytoplasm (center image; taken from an animal in the PVAc80% treatment group) 
and macrophages with a coarsely vacuolated cytoplasm (right image; taken from an animal 
in the PVAc60% treatment group). The prevalence of macrophages with finely vacuolated 
cytoplasm (b) and coarsely vacuolated cytoplasm (c), expressed as a percentage of the total 
macrophage population 24 h post-treatment with vehicle control, 22, and 220 cm
2
 of each 
nanomaterial. Columns represent the mean ± standard deviation from n=5-12 animals per 
group. (*) p <0.05, (**) p < 0.01, (***) p<0.001. 
 
Figure 7. J774 macrophage morphology and frequency of apoptosis in response to PVAc 
60% and PVAc80% nanoparticle exposure. Light transmission and confocal laser scanning 
micrographs of live J774 cells 24 h post-treatment with (a) cell culture medium (negative 
control), (b) 0.4 mg mL
-1
 PVA (PVAc nanoparticle vehicle control) or 0.5-10 mg/mL PVAc60% 
(c-e) and PVAc80% (f-h) nanoparticles. Green fluorescence depicts the presence of caspase 3/7 
activity (apoptosis), while the corresponding light transmission images highlight dose-dependent 
vacuolization in response to PVAc60% exposure (b-d). A semi-quantitative image analysis of the 
frequency of apoptotic cells (caspase 3/7 positive cells, % of total population) was calculated 
from analysis of three independent images per samples (i). (*) p <0.05, (**) p < 0.01, (***) 
p<0.001. 
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